Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

PleXus Communications
Avatar

HR+ Breast Cancer: Individualizing Therapy With CDK 4/6 Inhibitors

By PleXus Communications FEATURING Komal Jhaveri
By PleXus Communications FEATURING Komal Jhaveri
0 views
February 9, 2022
This activity is supported by an educational grant from Lilly. For further information concerning Lilly ...
read more ↘
Comments 1
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
Breast
06:55
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "EMBER Study - Imlunestrant+/-Everolimus or…

Feat. K. Jhaveri
21:26
Memorial Sloan Kettering Cancer Center

Early Diagnosis and Updates in Breast Cancer

Feat. V. Sacchini
27:27
Nebraska Oncology Society

ASCO 2022 HR+ Breast Cancer Updates

Feat. C. Dang
05:51
Nebraska Oncology Society

ASCO 2022 on the Phase 3 DESTINY-Breast 03 Trial: HER2+ BC Updates

Feat. C. Dang
09:47
Nebraska Oncology Society

ASCO 2022 on the Phase 3 KEYNOTE-522 Trial: TNBC Updates

Feat. C. Dang
09:57
ASCO 2022 Conference Coverage

ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fi…

Feat. C. Dang
01:06
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Preliminary Analysis of an Expanded Acce…

Feat. C. Dang
05:41
ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MB…

Feat. S. Modi
05:57
ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of …

Feat. S. Modi
06:32
ASCO 2022 Conference Coverage

ASCO 2022 on Characterization of Alpelisib-Associated Hyperglycemia …

Feat. S. Shen
01:37
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Characterization of Alpelisib-Associa…

Feat. S. Shen
20:08
Memorial Sloan Kettering Cancer Center

HER2- Directed Targeted Agents for Brain Metastasis in Metastatic Br…

Feat. N. Iyengar
28:05
University of Kansas Cancer Center Post San Antonio Review

2022 Inherited Breast Cancer Risk Assessment and Reduction: What…

Feat. M. Robson
53:46
PleXus Communications

HR+ Breast Cancer: Individualizing Therapy With CDK 4/6 Inhibitors

Feat. K. Jhaveri
07:16
SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Results of a Prospective Screening Study: Impact of Race …

Feat. A. Barrio
13:08
SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updates on Neratinib + Fulvestrant + Trastuzumab for HR+/…

Feat. K. Jhaveri
24:21
SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Update on Oligoprogressive Disease in BC: Treating Locall…

Feat. A. Xu
20:23
Memorial Sloan Kettering Cancer Center

Will Surgery Be a Part of Breast Cancer Treatment in the Future?

Feat. M. Morrow
26:50
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

CAR-T Cell Therapy for Breast Cancer: Types of T-Cell Therapy, Ident…

Feat. S. Modi